Равулизумаб (Ravulizumab)
Международное непатентованное наименование
Равулизумаб (Ravulizumab)
Торговое наименование
Ultomiris
Производитель, страна
Alexion Pharmaceuticals, USA
Лекарственная форма
weight-based doses of injection
Механизм действия
Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria and the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Клинические исследования
1.
Название протокола
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Дата начала и окончания КИ
May 2020 - February 2021
Название организации, проводящей КИ
Alexion Pharmaceuticals
Страны
USA
Фаза
III
Кол-во пациентов
270